Wells Fargo & Company Salarius Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.17 - $41.34 $4 - $1,033	-25 Reduced 6.67%	350 $0
Q2 2022 Aug 12, 2022	BUY	$0.16 - $0.42 $15 - $40	97 Added 34.89%	375 $0
Q1 2022 May 16, 2022	BUY	$0.34 - $0.54 $0 - $0	1 Added 0.36%	278 $0
Q4 2021 Feb 14, 2022	BUY	$0.49 - $1.01 $1 - $3	3 Added 1.09%	277 $0
Q3 2021 Nov 15, 2021	BUY	$0.8 - $1.15 $9 - $13	12 Added 4.58%	274 $0
Q2 2021 Aug 16, 2021	BUY	$1.02 - $1.52 $109 - $162	107 Added 69.03%	262 $0
Q1 2021 May 13, 2021	BUY	$1.0 - $3.0 $50 - $150	50 Added 47.62%	155 $0
Q4 2020 Feb 09, 2021	BUY	$0.65 - $1.34 $4 - $9	7 Added 7.14%	105 $0
Q3 2020 Nov 05, 2020	BUY	$0.77 - $1.52 $15 - $30	20 Added 25.64%	98 $0
Q2 2020 Aug 13, 2020	BUY	$0.6 - $1.82 $0 - $1	1 Added 1.3%	78 $0
Q1 2020 May 14, 2020	BUY	$0.56 - $3.82 $43 - $294	77 New	77 $0

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.73M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.